« Back
Home /
Ruxolitinib

Ruxolitinib

Item no.	HY-50856-1g
Manufacturer	MedChem Express
CASRN	941678-49-5
Amount	1 g
Quantity options	100 mg 10 mM/1 mL 10 mg 1 g 1 mg 200 mg 500 mg 50 mg 5 mg
Category	Food Safety Hormones Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.99
Citations	[1]Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.\|[2]Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366(9), 799-807.\|[3]Tavallai M, et al. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.Front Oncol. 2016 Jun 13;6:142. ACS Chem Biol. 2017 May 19;12(5):1245-1256. Acta Pharmacol Sin. 2021 May;42(5):814-823. Adv Funct Mater. 2025 Apr 21. Adv Healthc Mater. 2025 Jul 22:e01838. Adv Sci (Weinh). 2021 Jan 6;8(5):2002738. AIDS. 2016 Aug 24;30(13):2053-64. Anim Reprod Sci. 2025 Apr 28:277:107850. Ann Rheum Dis. 2025 Sep 25:S0003-4967(25)04383-3. Biochem Biophys Res Commun. 2020 May 7;525(3):662-667. Biochem Pharmacol. 2020 Aug;178:114103. Biochem Pharmacol. 2025 Jun 24:117088. Biochim Biophys Acta Mol Basis Dis. 2025 Sep 18;1872(1):168056. Biomed Pharmacother. 2023 Aug:164:114902. Biomedicines. 2022 Apr 18;10(4):928. bioRxiv. 2021 Feb 5. bioRxiv. 2023 May 22:2023.05.22.541644. bioRxiv. 2024 Aug 8:2024.08.06.606693. bioRxiv. 2024 Dec 3:2024.11.27.625710. bioRxiv. 2025 Aug 21:2025.08.15.670603. bioRxiv. 2025 February 21. bioRxiv. 2025 January 31. bioRxiv. 2025 Jul 8:2025.07.04.663209. bioRxiv. 2025 Jun 3:2025.06.02.657064. bioRxiv. 2025 June 03. bioRxiv. 2025 Mar 17:2025.03.14.643359. bioRxiv. 2025 Nov 20. bioRxiv. 2025 Oct 22. bioRxiv. 2025 Sep 21. Blood Adv. 2025 Aug 19:bloodadvances.2025016898. Blood Adv. 2025 Jul 2:bloodadvances.2024015322. blood advances. 2018 Dec 11;2(23):3428-3442. Blood Sci. 2023 Jul 12;5(4):258-268. Blood. 2014 Dec 18;124(26):3924-31. Cancer Biol Ther. 2023 Dec 31;24(1):2269637. Cancer Cell Int. 2015 Mar 12:15:30. Cancer Commun (Lond). 2021 Dec;41(12):1354-1372. Cancer Discov. 2024 Oct 4;14(10):1964-1989. Cancer Immunol Res. 2025 Jan 9:OF1-OF19. Cancer Res. 2023 Jan 18;83(2):264-284. Cancer Sci. 2021 Mar;112(3):997-1010. Cancers (Basel). 2022 Dec 31;15(1):296. Cancers (Basel). 2024 Apr 16, 16(8), 1511. Cancers (Basel). 2024 Apr 16;16(8):1511. Cell Biosci. 2021 Aug 4;11(1):156. Cell Cycle. 2020 Aug;19(16):2074-2080. Cell Death Dis. 2020 Nov 15;11(11):982. Cell Death Dis. 2022 May 25;13(5):496. Cell Death Dis. 2025 Jan 26;16(1):46. Cell Death Discov. 2025 Oct 24;11(1):483. Cell Mol Biol Lett. 2024 Feb 2;29(1):22. Cell Mol Gastroenterol Hepatol. 2024;17(2):219-235. Cell Mol Immunol. 2022 Nov;19(11):1263-1278. Cell Mol Immunol. 2022 Oct;19(10):1130-1140. Cell Rep Med. 2024 Dec 3:101849. Cell Rep Med. 2024 Mar 19;5(3):101472. Cell Rep. 2020 Sep 15;32(11):108158. Cell Rep. 2023 Mar 30;42(4):112327. Cell Rep. 2024 Apr 23;43(4):114111. Cell Rep. 2024 Oct 11;43(10):114866. Cell Rep. 2025 Oct 29;44(11):116480. Cell Signal. 2025 Jul:131:111706. Cell Syst. 2018 Apr 25;6(4):424-443.e7. Cell. 2021 Apr 15;184(8):2167-2182.e22. Cell. 2024 Apr 25;187(9):2288-2304.e27. Chemosphere. 2021 Jan;263:127849. Clin Cancer Res. 2018 Apr 15;24(8):1917-1931. Clin Cosmet Investig Dermatol. 2025 Apr 24:18:999-1009. Clin Exp Dermatol. 2021 Jul;46(5):880-887. Clin Exp Immunol. 2021 Nov 27;207(1):113-122. Clin Exp Immunol. 2022 Jan 28;207(1):113-122. Columbia University. 2024. Cytojournal. 2024 Dec 20:21:69. Dev Cell. 2025 Aug 25:S1534-5807(25)00499-X. EMBO Mol Med. 2025 Oct 30. Emerg Microbes Infect. 2023 Dec;12(1):2178238. Endocr Relat Cancer. 2023 Jul 25;30(9):e230130. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):625-635. Eur J Haematol. 2023 Apr;110(4):435-443. Eur J Pharmacol. 2022 Apr 5:920:174822. Exp Dermatol. 2025 Jul;34(7):e70132. Exp Eye Res. 2021 Jan;202:108375. Exp Hematol. 2022 May:109:55-67.e2. FASEB J. 2025 Sep 30;39(18):e71032. FEBS J. 2022 Apr;289(7):1968-1983. Free Radic Biol Med. 2025 Nov:239:91-103. Front Oncol. 2021 Aug 6:11:629350. Fundam Clin Pharmacol. 2021 Oct;35(5):919-929. Gut. 2020 Jan;69(1):122-132. Harvard Medical School. June 13, 2018 Harvard University. 2024 May. Hemasphere. 2021 Aug 11;5(9):e630. Inflammation. 2025 Jan 13. Int Immunopharmacol. 2023 Mar:116:109723. Int Immunopharmacol. 2024 Dec 25:146:113817. Int Immunopharmacol. 2025 Jan 17:148:113972. Int Immunopharmacol. 2025 Oct 30:164:115351. Int J Biol Macromol. 2025 Jan 17:298:140025. Int J Clin Exp Pathol. 2017;10(3):3033-3042. Int J Med Microbiol. 2020 Oct;310(7):151450. Int J Mol Sci. 2022 Apr 12;23(8):4277. Int J Mol Sci. 2022 Dec 9;23(24):15646. Int J Mol Sci. 2022 May; 23(9): 5156. Int J Mol Sci. 2023 Apr 13;24(8):7219. Int J Mol Sci. 2023 May 25;24(11):9243. Int J Mol Sci. 2025 Jun 26;26(13):6123. Int J Oral Sci. 2025 Mar 19;17(1):22. Invest New Drugs. 2022 Dec;40(6):1194-1205. iScience. 2021 Sep 25;24(10):103173. iScience. 2024 May 16. J Adv Res. 2023 May:47:151-162. J Agric Food Chem. 2015 Apr 8;63(13):3472-80. J Biol Chem. 2015 Nov 27;290(48):29022-34. J Biotechnol. 2025 Mar:399:9-18. J Cell Mol Med. 2021 Jan;25(2):1089-1099. J Cell Mol Med. 2022 Jul;26(14):3902-3912. J Cell Mol Med. 2025 Jul;29(14):e70720. J Clin Invest. 2021 Dec 15;131(24):e145501. J Exp Clin Cancer Res. 2025 Jun 5;44(1):172. J Exp Med. 2024 Jul 1;221(7):e20240111. J Exp Med. 2024 Mar 4;221(3):e20230683. J Exp Med. 2024 Mar 4;221(3):e20232028. J Immunother Cancer. 2025 May 11;13(5):e010831. J Inflamm Res. 2025 Oct 9:18:14075-14096. J Leukoc Biol. 2022 Nov;112(5):1343-1356. J Leukoc Biol. 2025 Dec 1;117(12):qiaf157. J Med Virol. 2023 Nov;95(11):e29230. J Mol Histol. 2025 Nov 24;57(1):4. J Pharmacol Exp Ther. 2025 Oct 31;393(1):103767. J Physiol Investig. 2025 Mar 1;68(2):109-119. J Vet Sci. 2021 May;22(3):e39. J Virol. 2024 Jun 28:e0073824. J Virol. 2025 Aug 18:e0113025. J Virol. 2025 Jun 17;99(6):e0046925. JCI Insight. 2018 Sep 6;3(17). pii: 120750. JCI Insight. 2024 Oct 29:e173665. JCI Insight. 2025 Jul 8;10(13):e188843. Kaohsiung J Med Sci. 2023 Jan;39(1):26-39. Leuk Lymphoma. 2023 Jan;64(1):71-78. Leukemia. 2012 Oct;26(10):2233-44. Leukemia. 2023 May;37(5):1068-1079. Metab Brain Dis. 2023 Mar;38(3):945-960. Metab Brain Dis. 2025 Oct 30;40(8):301. Mol Biol Rep. 2023 Jan;50(1):319-329. Mol Biol Rep. 2024 Jul 22;51(1):832. Mol Biomed. 2025 Apr 8;6(1):21. Mol Cell Biochem. 2025 Apr;480(4):2645-2660. Mol Genet Genomics. 2025 Feb 22;300(1):23. Mol Med. 2025 May 13;31(1):184. Mol Ther Nucleic Acids. 2025 Mar 5;36(2):102502. Nat Biomed Eng. 2025 Oct 22. Nat Cancer. 2022 Sep;3(9):1071-1087. Nat Cancer. 2025 Sep;6(9):1537-1558. Nat Cell Biol. 2025 Nov 17. Nat Chem Biol. 2025 Apr 25. Nat Commun. 2021 Aug 13;12(1):4917. Nat Commun. 2023 Apr 24;14(1):2342. Nat Commun. 2023 May 10;14(1):2685. Nat Commun. 2024 Aug 26;15(1):7165. Nat Commun. 2024 Aug 6;15(1):6685. Nat Commun. 2024 Jan 10;15(1):446. Nat Commun. 2025 Aug 4;16(1):7134. Nat Commun. 2025 Jul 29;16(1):6972. Nat Commun. 2025 Jul 8;16(1):6270. Nat Commun. 2025 Nov 20;16(1):10222. Nat Commun. 2025 Sep 29;16(1):8560. Nat Med. 2018 Aug;24(8):1143-1150. Nature. 2022 Sep;609(7928):785-792. Nature. 2023 Mar;615(7950):158-167. Nature. 2025 Jan;637(8046):726-735. Neuroscience Research Notes. 2025 Feb 02. Neurotoxicology. 2024 Aug 27:S0161-813X(24)00100-1. Nutrients. 2019 Apr 5;11(4):791. Oncogenesis. 2019 Feb 22;8(3):15. Oncol Rep. 2018 Aug;40(2):635-646. Oncol Rep. 2024 May;51(5):71. Oncol Rep. 2025 Mar;53(3):40. Patent. US20180263995A1. Patent. US20210025893A1. Patent. US20220305048A1. Pennsylvania State University. 2025. PLoS Biol. 2023 Mar 17;21(3):e3002039. PLoS Genet. 2024 May 28;20(5):e1011293. PLoS One. 2017 Jun 30;12(6):e0180244. PLoS One. 2021 Sep 30;16(9):e0258140. PLoS One. 2022 Oct 14;17(10):e0276010. PLoS One. 2024 Nov 1;19(11):e0308647. PLoS Pathog. 2025 Oct 27;21(10):e1013623. Poultry Sci. 2021 May;100(5):101085. Preprints. 2025 May 08. Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119. Proc Natl Acad Sci U S A. 2024 Nov 5;121(45):e2412725121. Res Sq. 2024 Jun 13. Res Sq. 2025 Apr 14. Res Sq. 2025 Sep 25. Research Square Preprint. 2023 Sep 11. Research Square Print. August 22nd, 2022. Ruperto Carola University Heidelberg. 2023 Jun 1. Sci Adv. 2024 Aug 9;10(32):eadn9519. Sci Adv. 2024 Mar 22;10(12):eadl0368. Sci Immunol. 2024 Jul 12;9(97):eadn0178. Sci Rep. 2021 Feb 15;11(1):3847. Sci Rep. 2024 Oct 10;14(1):23725. Sci Rep. 2025 May 15;15(1):16869. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Sci Transl Med. 2022 Aug 10;14(657):eabg3277. Signal Transduct Target Ther. 2024 Mar 9;9(1):65. SSRN. 2025 Feb 11. SSRN. 2025 Jul 26. Talanta. 2020 Feb 1;208:120450. Theranostics. 2022 Oct 3;12(16):7051-7066. Université de Lausanne. 2024 Feb 7. University of Düsseldorf. 2024. University of Michigan. Cellular and Molecular Biology. 2022 Aug. University of Pennsylvania. 2025. University of Washington. 2025. University of Zürich. Department of Dermatology. 2021 Dec. Vet Microbiol. 2022 Dec:275:109594. Vet Microbiol. 2025 Apr:303:110444. View. 2025 Oct 28. Virology. 2024 Sep 14:600:110245. Virology. 2025 May 13:609:110574. Adv Funct Mater. 2025 Apr 21. bioRxiv. 2025 Oct 22. Blood. 2013 Nov 21;122(22):3628-31. Cancer Discov. 2018 May;8(5):616-631. EMBO Mol Med. 2025 Aug;17(8):2040-2070. Haematologica. 2020 Jan;105(1):124-135. Harvard Medical School LINCS LIBRARY Inflamm Res. 2015 Jan;64(1):41-51. Int J Biol Macromol. 2022 Jan 1:194:153-162. J Hematol Oncol. 2021 Jun 24;14(1):97. N Engl J Med. 2024 May 30;390(20):1873-1884. Neuroscience. 2019 Dec 1;422:12-20. Oncotarget. 2017 Oct 4;8(55):94040-94053. Patent. US20250228857A1.
Smiles	N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	INCB18424
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Apoptosis; Autophagy; JAK; Mitophagy
Manufacturer - HS Code	H302
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	306.37
Product Description	Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3[1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy[3].
Manufacturer - Research Area	Cancer
Solubility	H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Clinical information	Launched
Isoform	JAK1; JAK2; JAK3; Tyk2
UNSPSC Code	12352005
Precautionary	H302

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.